Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes will comply with the requirements of the protocol should be enrolled in the study.~* A male or female between, and including, 18 and 40 years of age at the time of the first vaccination.~* Written informed consent obtained from the subject.~* Subject without medical history, clinical finding or laboratory finding, which, in the opinion of the investigator, could pose a safety concern or interfere with the protocol.~* If the subject is female, and of childbearing potential, she agrees to use adequate contraception and not become pregnant for the duration of the study.~Exclusion Criteria:~* Pneumonia within 3 years prior to 1st vaccination.~* Invasive Pneumococcal Disease within 3 years prior to 1st vaccination.~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period or participation to another pharmaceutical/vaccine study.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccines, with the exception of the influenza vaccine which can be administered \>14 days prior to or \>14 days following vaccine doses 1 and 2.~* Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.~* History of reaction or hypersensitivity to any component of the vaccine.~* Any serious, uncontrolled disease likely to interfere with the study as determined by history, physical examination or laboratory screening, as per the judgment of the Investigator.~* Inflammatory processes such as known chronic infections.~* All past or current malignancies and lymphoproliferative disorders.~* Laboratory evidence of haematological and biochemical abnormalities.~* Acute disease at the time of enrolment/vaccination.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.~* History of chronic alcohol consumption and/or drug abuse.~* Other conditions that the principal investigator judges may interfere with study findings.~* Previous vaccination for hepatitis B. As a portion of the subjects will be randomized to receive Engerix-B comparator, it is important that all subjects meet Engerix-B eligibility criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- GSK2254233A Group (Type: EXPERIMENTAL): Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
- GSK2254232A Group (Type: EXPERIMENTAL): Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
- Engerix Group (Type: ACTIVE_COMPARATOR): Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).